These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 39275990)

  • 1. Real-time continuous glucose monitoring vs. self-monitoring of blood glucose: cost-utility in South Korean type 2 diabetes patients on intensive insulin.
    Kim JY; Ilham S; Alshannaq H; Pollock RF; Ahmed W; Norman GJ; Jin SM; Kim JH
    J Med Econ; 2024; 27(1):1245-1252. PubMed ID: 39275990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in France.
    Alshannaq H; Pollock RF; Joubert M; Ahmed W; Norman GJ; Lynch PM; Roze S
    J Comp Eff Res; 2024 Mar; 13(3):e230174. PubMed ID: 38294332
    [No Abstract]   [Full Text] [Related]  

  • 3. Continuous glucose monitoring for self-management of diabetes in people living with type 2 diabetes mellitus on basal insulin therapy: A microsimulation model and cost-effectiveness analysis from a US perspective with relevance to Medicaid.
    Frank J; Son D; Szafranski K; Poon Y
    J Manag Care Spec Pharm; 2024 Sep; 30(9):917-928. PubMed ID: 39109990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis of a flash continuous glucose monitoring system in the management of people with type 2 diabetes mellitus on basal insulin therapy-An Italian healthcare system perspective.
    Del Prato S; Giorgino F; Szafranski K; Poon Y
    Diabetes Obes Metab; 2024 Sep; 26(9):3633-3641. PubMed ID: 38853717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose and intermittently scanned continuous glucose monitoring in people with type 1 diabetes receiving multiple daily insulin injections in Denmark.
    Alshannaq H; Cogswell G; Pollock RF; Ahmed W; Norman GJ; Lynch PM; Roze S
    Diabetes Obes Metab; 2023 Sep; 25(9):2704-2713. PubMed ID: 37334522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type 2 diabetes in Canada.
    Alshannaq H; Isitt JJ; Pollock RF; Norman GJ; Cogswell G; Lynch PM; Roze S
    J Comp Eff Res; 2023 Oct; 12(10):e230075. PubMed ID: 37668608
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term Cost-Effectiveness of Dexcom G6 Real-time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Patients With Type 1 Diabetes in the U.K.
    Roze S; Isitt J; Smith-Palmer J; Javanbakht M; Lynch P
    Diabetes Care; 2020 Oct; 43(10):2411-2417. PubMed ID: 32647050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of G5 Mobile continuous glucose monitoring device compared to self-monitoring of blood glucose alone for people with type 1 diabetes from the Canadian societal perspective.
    Chaugule S; Graham C
    J Med Econ; 2017 Nov; 20(11):1128-1135. PubMed ID: 28745578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.
    Lee KH; Seo SJ; Smith-Palmer J; Palmer JL; White J; Valentine WJ
    Value Health; 2009; 12 Suppl 3():S55-61. PubMed ID: 20586983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term cost-effectiveness of Dexcom G6 real-time continuous glucose monitoring system in people with type 1 diabetes in Australia.
    Isitt JJ; Roze S; Tilden D; Arora N; Palmer AJ; Jones T; Rentoul D; Lynch P
    Diabet Med; 2022 Jul; 39(7):e14831. PubMed ID: 35298036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation.
    Riemsma R; Corro Ramos I; Birnie R; Büyükkaramikli N; Armstrong N; Ryder S; Duffy S; Worthy G; Al M; Severens J; Kleijnen J
    Health Technol Assess; 2016 Feb; 20(17):v-xxxi, 1-251. PubMed ID: 26933827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Cost-Effectiveness of Real-Time Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes.
    Fonda SJ; Graham C; Munakata J; Powers JM; Price D; Vigersky RA
    J Diabetes Sci Technol; 2016 Jul; 10(4):898-904. PubMed ID: 26843480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of continuous subcutaneous insulin infusion in people with type 2 diabetes in the Netherlands.
    Roze S; Duteil E; Smith-Palmer J; de Portu S; Valentine W; de Brouwer BF; Reznik Y; de Valk HW
    J Med Econ; 2016 Aug; 19(8):742-9. PubMed ID: 26985982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System Compared to Standard Management of Type 1 Diabetes in a Singapore Setting.
    Gardner D; Lakkad M; Qiu Z; Inoue Y; Rama Chandran S; Wherry K
    Diabetes Technol Ther; 2024 May; 26(5):324-334. PubMed ID: 38215206
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: The DIAMOND Randomized Trial.
    Wan W; Skandari MR; Minc A; Nathan AG; Winn A; Zarei P; O'Grady M; Huang ES
    Diabetes Care; 2018 Jun; 41(6):1227-1234. PubMed ID: 29650803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Sensor-Augmented Insulin Pump Therapy Versus Continuous Insulin Infusion in Patients with Type 1 Diabetes in Turkey.
    Roze S; Smith-Palmer J; de Portu S; Özdemir Saltik AZ; Akgül T; Deyneli O
    Diabetes Technol Ther; 2019 Dec; 21(12):727-735. PubMed ID: 31509715
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-Effectiveness of Sensor-Augmented Pump Therapy with Low Glucose Suspend Versus Standard Insulin Pump Therapy in Two Different Patient Populations with Type 1 Diabetes in France.
    Roze S; Smith-Palmer J; Valentine W; Payet V; de Portu S; Papo N; Cucherat M; Hanaire H
    Diabetes Technol Ther; 2016 Feb; 18(2):75-84. PubMed ID: 26646072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of a Real-Time Continuous Glucose Monitoring System Versus Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Therapy in the UK.
    Isitt JJ; Roze S; Sharland H; Cogswell G; Alshannaq H; Norman GJ; Lynch PM
    Diabetes Ther; 2022 Dec; 13(11-12):1875-1890. PubMed ID: 36258158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of sensor-augmented pump therapy in two different patient populations with type 1 diabetes in Italy.
    Nicolucci A; Rossi MC; D'Ostilio D; Delbaere A; de Portu S; Roze S
    Nutr Metab Cardiovasc Dis; 2018 Jul; 28(7):707-715. PubMed ID: 29753586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Cost-Effectiveness of Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Adults With Type 1 Diabetes in Iran.
    Molaee MC; Naseri ZG; Karami MA
    Value Health Reg Issues; 2024 Sep; 43():101002. PubMed ID: 38820700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.